AHEAD 3-45 (BAN2401-G000-303)
Official Title
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimers Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimers Disease and Intermediate Amyloid (A3 Trial)
Study Details
The AHEAD Study is testing whether an investigational treatment can lower people’s risk of memory loss due to Alzheimer’s disease.
Principal Investigator
Dr. Barbara Snider
IRB Number
202005011
Eligibility
1. Participants must be 55 to 80 years old
2. Participants must be at risk of developing symptoms of Alzheimer’s disease as they get older
3. Currently only seeking participants of non-Caucasian race
Compensation is provided for time and effort (contact the study team for compensation amount).
Volunteer Information
For more information about this study, contact Volunteer for Health at:
- 314.362.1000
- rprstaff@wustl.edu